publication venue for
- Cardiovascular protection: a breakthrough for high-risk patients 2009
- Clinical evidence from ONTARGET: proven cardio- and vascular protection 2009
- Haemodynamic and neurohormonal effects ofAT-receptor Blockers 2004
- Long-term management of unstable angina and non-Q-wave myocardial infarction 2000
- Clinical trials of low molecular weight heparins 1999
- Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: assessing net clinical benefit. 26:iv4-iv11. 2024
- Dear colleagues: enough with the men-only author panels. 24:L53-L56. 2022
- Improving worldwide access to inexpensive and effective treatments for common cardiovascular diseases. 20:C18-C22. 2018
- Continued commitment to safety: building on the existing rivaroxaban knowledge base: Table 1. 17:D21-D28. 2015
- Clinical benefit and practical use of fondaparinux in the invasive management of patients with acute coronary syndromes. 10:C14-C21. 2008
- Effect of fondaparinux 2.5 mg once daily on mortality: a meta-analysis of phase III randomized trials of venous thromboembolism prevention. 10:C8-C13. 2008
- Selective factor Xa inhibition with fondaparinux: from concept to clinical benefit. 10:C1-C7. 2008
- Atrial fibrillation in the ‘real world’: undecided issues. 9:I122-I128. 2007
- Bleeding and management of bleeding. 8:G38-G45. 2006
- Clopidogrel in non-ST-segment elevation acute coronary syndromes. 8:G25-G30. 2006
- Emerging therapies for stroke prevention in atrial fibrillation. 7:C19-C27. 2005
- Risk of bleeding with long-term antithrombotic therapy in atrial fibrillation. 7:C34-C40. 2005
- Haemodynamic and neurohormonal effects of AT1-receptor blockers. 6:h49-h54. 2004
- A disturbed glucose metabolic state (dysglycaemia) is a key risk factor for cardiovascular events. 5:B1-B2. 2003
- Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies. 5:A43-A48. 2003